Biotechnology Companies By Net Asset

Net Asset
Net AssetEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
135.16 B
 0.08 
 1.70 
 0.14 
2AMGN Amgen Inc
91.84 B
 0.15 
 1.86 
 0.28 
3GILD Gilead Sciences
58.99 B
 0.06 
 1.50 
 0.09 
4GMAB Genmab AS
45.81 B
 0.12 
 1.93 
 0.24 
5REGN Regeneron Pharmaceuticals
37.76 B
 0.17 
 2.50 
 0.43 
6HLN Haleon plc
34.31 B
(0.02)
 1.35 
(0.03)
7NEUP Neuphoria Therapeutics
28.59 B
(0.04)
 13.86 
(0.49)
8BIIB Biogen Inc
28.05 B
 0.20 
 2.06 
 0.41 
9VRTX Vertex Pharmaceuticals
22.53 B
 0.15 
 1.57 
 0.23 
10BNTX BioNTech SE
22.53 B
(0.04)
 2.13 
(0.08)
11GRFS Grifols SA ADR
21.41 B
(0.11)
 1.73 
(0.19)
12MRNA Moderna
14.14 B
 0.06 
 4.08 
 0.25 
13SVA Sinovac Biotech
13.66 B
 0.00 
 0.00 
 0.00 
14UTHR United Therapeutics
7.36 B
 0.19 
 1.90 
 0.35 
15BMRN Biomarin Pharmaceutical
6.99 B
(0.04)
 1.70 
(0.07)
16ARGX argenx NV ADR
6.2 B
 0.19 
 1.38 
 0.26 
17EXAS EXACT Sciences
5.93 B
 0.27 
 3.87 
 1.05 
18ONC BeiGene,
5.92 B
(0.02)
 2.94 
(0.07)
19INCY Incyte
5.44 B
 0.15 
 1.86 
 0.28 
20ROIV Roivant Sciences
5.44 B
 0.39 
 1.99 
 0.78 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund. Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.